Literature DB >> 16387803

Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.

Richard A Belkin1, Noreen R Henig, Lianne G Singer, Cecilia Chaparro, Ronald C Rubenstein, Sharon X Xie, Justin Y Yee, Robert M Kotloff, David A Lipson, Greta R Bunin.   

Abstract

RATIONALE: The optimal timing for listing of cystic fibrosis patients for lung transplantation is controversial.
OBJECTIVES: We conducted a retrospective cohort study of 343 patients listed for lung transplantation at four academic medical centers to identify risk factors for death while awaiting transplantation.
METHODS: Data on possible risk factors were abstracted from medical records. MEASUREMENTS: Time to death, patient demographic characteristics, and risk factors for death while awaiting transplantation were assessed. Univariate and multivariate survival analyses were performed using Cox regression.
RESULTS: By univariate analyses, FEV1 < or = 30% predicted (HR, 3.8; 95% CI, 2.0-7.5), Pa(CO2) > or = 50 mm Hg (HR, 1.85; 95% CI, 1.1-3.0), and shorter height (HR, 1.8; 95% CI, 1.1-3.0) were associated with a higher risk of death. Referral from an accredited cystic fibrosis center was associated with a lower risk (HR, 0.53; 95% CI, 0.30-0.92). The final multivariate model included referral from an accredited cystic fibrosis center (HR, 0.5; 95% CI, 0.3-1.0) and listing year after 1996 (HR, 0.4; 95% CI, 0.2-0.7); both were associated with a lower risk of death. FEV1 < or = 30% predicted (HR, 6.8; 95% CI, 2.4-19.3), Pa(CO2) > or = 50 mm Hg (HR, 6.9; 95% CI, 1.5-32.1), and use of a nutritional intervention (HR, 2.3; 95% CI, 1.3-4.1) were associated with increased risk. Patients with FEV1 > 30% predicted had a higher risk of death only when their Pa(CO2) was > or = 50 mm Hg (HR, 7.0; 95% CI, 1.5-32), while the increased risk of death with FEV1 < or = 30% was not further influenced by the presence of hypercapnia.
CONCLUSIONS: We identified risk factors for waiting list mortality that could impact on transplant listing and allocation guidelines.

Entities:  

Mesh:

Year:  2005        PMID: 16387803      PMCID: PMC2662949          DOI: 10.1164/rccm.200410-1369OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

Review 1.  Lung transplantation.

Authors:  S M Arcasoy; R M Kotloff
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Stature as a prognostic factor in cystic fibrosis survival.

Authors:  L T Beker; E Russek-Cohen; R J Fink
Journal:  J Am Diet Assoc       Date:  2001-04

4.  Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease.

Authors:  J D Hosenpud; L E Bennett; B M Keck; E B Edwards; R J Novick
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

5.  Survival effect of lung transplantation among patients with cystic fibrosis.

Authors:  T G Liou; F R Adler; B C Cahill; S C FitzSimmons; D Huang; J R Hibbs; B C Marshall
Journal:  JAMA       Date:  2001-12-05       Impact factor: 56.272

6.  Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia.

Authors:  K L Fraser; D E Tullis; Z Sasson; R H Hyland; K S Thornley; P J Hanly
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

Review 7.  Lung transplantation in cystic fibrosis: consensus conference statement.

Authors:  J R Yankaskas; G B Mallory
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

8.  Use of lung transplantation survival models to refine patient selection in cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; David Huang
Journal:  Am J Respir Crit Care Med       Date:  2005-02-01       Impact factor: 21.405

9.  Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection.

Authors:  C A Demko; P J Byard; P B Davis
Journal:  J Clin Epidemiol       Date:  1995-08       Impact factor: 6.437

10.  Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis.

Authors:  N N Huang; D V Schidlow; T H Szatrowski; J Palmer; L R Laraya-Cuasay; W Yeung; K Hardy; L Quitell; S Fiel
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

View more
  48 in total

Review 1.  Update in cystic fibrosis 2006.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2007-04-15       Impact factor: 21.405

Review 2.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 3.  Effects of hypercapnia on the lung.

Authors:  Masahiko Shigemura; Emilia Lecuona; Jacob I Sznajder
Journal:  J Physiol       Date:  2017-02-14       Impact factor: 5.182

4.  The utility of preoperative six-minute-walk distance in lung transplantation.

Authors:  Anthony W Castleberry; Brian R Englum; Laurie D Snyder; Mathias Worni; Asishana A Osho; Brian C Gulack; Scott M Palmer; R Duane Davis; Matthew G Hartwig
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

Review 5.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

Review 6.  Update in cystic fibrosis 2012.

Authors:  Christopher H Goss; Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2013-05-01       Impact factor: 21.405

Review 7.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

Review 8.  Carbon dioxide-sensing in organisms and its implications for human disease.

Authors:  Eoin P Cummins; Andrew C Selfridge; Peter H Sporn; Jacob I Sznajder; Cormac T Taylor
Journal:  Cell Mol Life Sci       Date:  2013-09-18       Impact factor: 9.261

Review 9.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

10.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.